Copyright
©The Author(s) 2017.
World J Gastroenterol. Sep 14, 2017; 23(34): 6294-6305
Published online Sep 14, 2017. doi: 10.3748/wjg.v23.i34.6294
Published online Sep 14, 2017. doi: 10.3748/wjg.v23.i34.6294
Table 1 Clinical and reimbursement guidelines
Country | Guideline | Source, organization, last update, web-link |
The Czech Republic | Clinical | Bortlík et al[25] 2016 by IBD Working Group of the Czech Society of Gastroenterology |
Reimbursement | Reimbursement criteria of the SUKL1; Edited by: SUKL, http://www.sukl.cz | |
France | Clinical | ECCO guidelines, Crohn's Disease Guidelines (2010), Check list ANTI TNF, Check list VEDOLIZUMAB by GETAID2https://www.getaid.org/recommandations.html |
Reimbursement | No | |
Germany | Clinical | German Guidelines on Crohn’s disease; DGVS German Society of Gastroenterology (2014) |
Reimbursement | No | |
Hungary | Clinical | Miheller et al[26] 2009 |
Reimbursement | The diagnostic and treatment of Crohn’s disease] by NHIFA3 (2013) http://www.oep.hu/data/cms989735/0626_a_felnottkori_crohn_betegseg_diagnosztikajanak_es_kezelesenek_finanszirozasi_protokollja.pdf | |
Latvia | Clinical | No national guideline, but following the ECCO guideline |
Reimbursement | National Health Service of Latvia. No specific document, but part of the general regulations on medication reimbursement.(2016) | |
Poland | Clinical | [The treatment of Crohn’s Disease (ICD-10 K 50)], National Health Fund, (2014) http://onkologia-online.pl/upload/obwieszczenie/2015.10.28/b/b.32.pdf |
Reimbursement | No | |
Romania | Clinical | National Insurance Fund Protocol (2013) http://www.cnas.ro/default/index/index/lang/EN |
Reimbursement | National Insurance Fund protocol (2013) http://www.cnas.ro/default/index/index/lang/EN | |
Slovakia | Clinical | No national guideline, but following the ECCO guideline |
Reimbursement | Protocol for starting and continuing the biological treatment. Date first approvals: infliximab 2005, adalimumab 2008, vedolizumab 2016; The Slovakian Gastroenterology Association and The Union of Health Insurance Companies. | |
Spain | Clinical | Guidelines for biologics by GETECCU4 (2013) http://geteccu.org/formacion/guias-y-documentos-de-consenso; Cabriada et al[27] 2013 |
Reimbursement | No | |
Sweden | Clinical | (1) National Guidelines for the treatment of Crohn’s disease; The Swedish Society of Gastroenterology (2017) http://www.svenskgastroenterologi.se/sites/default/files/pagefiles/Riktlinjer_Lakemedelsbehandling_vid_Crohns_2012.pdf |
(2) The use of IFX biosimilar in patients with IBD; Swedish Society of Gastroenterology (2017) http://www.svenskgastroenterologi.se/sites/default/files/pagefiles/SGF_riktlinjer_Biosimilarer_150903.pdf | ||
(3) The Medical Product Agency: Drug treatment of IBD, novel recommendations by the Medical Product Agency, Sweden (2012) https://lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/L%C3%A4kemedelsbehandling%20vid%20inflammatorisk%20tarmsjukdom%20-%20ny%20rekommendation_bokm%C3%A4rken.pdf | ||
Reimbursement | No |
- Citation: Péntek M, Lakatos PL, Oorsprong T, Gulácsi L, Pavlova M, Groot W, Rencz F, Brodszky V, Baji P, Crohn’s Disease Research Group. Access to biologicals in Crohn’s disease in ten European countries. World J Gastroenterol 2017; 23(34): 6294-6305
- URL: https://www.wjgnet.com/1007-9327/full/v23/i34/6294.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i34.6294